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Background
The increasing frequency of methicillin-resistant Staphy-
lococcus aureus as a cause of surgical site infections,
and decreased susceptibility to vancomycin, highlight
the need for alternative therapies. Daptomycin is a novel
lipopeptide antibiotic used in the treatment of certain
infections caused by Gram-positive organisms. It is a
naturally-occurring compound found in the soil sapro-
troph Streptomyces roseosporus. Its distinct mechanism
of action means that it may be useful in treating infec-
tions caused by multi-resistant bacteria Daptomycin is
approved for the treatment of skin and skin-structure
infections (4 mg/kg), and Staphylococcus aureus bacter-
emia, including right-sided endocarditis (6 mg/kg).
Aim
To evaluate the safety and efficacy of daptomycin when
administered for a variety of gram-positive infections in
a single neurosurgical unit.
Materials and methods
During the last three years we use damtomycin (2006-
2007-2008) in 64 cases. For the purpose of this study,
the safety and efficacy of daptomycin were evaluated in
patients who received doses of 4 mg/kg or higher. Prior
antibiotic therapy was given to 21,8% of patients (14).
Results
The median final daptomycin dose was 5 mg/kg. The
median duration of daptomycin therapy was 15 days.
Daptomycin was well tolerated in patients with gram-
positive infections.The most common infections were
skin and skin-structure. The most common pathogens
were S. aureus.
1. A large number of novel antibacterial agents have
been or are being developed for the treatment of com-
plicated skin and soft tissue infections -cSSTIs -Dapto-
mycin is one of them and it is available for clinical use.
2.Daptomycin was well tolerated in patients with gram-
positive infections. 3. Further prospective and compara-
tive studies of daptomycin are warranted.
Conclusions
We have always to rememder that the most mportant
parameters that appear to determine the clinical effec-
tiveness of an antibiotic for cSSTIs include the severity
of the illness, patient co-morbidities, whether the patient
receives appropriate antimicrobial therapy at the onset
of illness and if this should be a combination or single-
agent approach to cover a broad range of likely causa-
tive organisms.
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